Recent Posts
News•Feb 27, 2026
Omics in Orlando Day 2: A Video Report From AGBT
The AGBT Day 2 video recap features Julianna LeMieux and Kevin Davies highlighting the meeting’s headline announcements. Vizgen unveiled a spatial‑omics platform aimed at organoid research, while Illumina introduced the TruPath Genome product, formerly known as Constellation mapped reads. Bruker launched two spatial analysis tools—CellScape and PaintScape—and 10x Genomics teased a novelty chocolate‑bar themed assay alongside Cellanome’s new single‑cell technology. A follow‑up GEN Live session on March 2 will dissect these developments with four leading experts.
By GEN (Genetic Engineering & Biotechnology News)
News•Feb 27, 2026
Mutant P53 Selective Reactivation Demonstrated in Advanced Solid Tumors
PMV Pharmaceuticals reported Phase I results of rezatapopt, a small‑molecule p53 reactivator, in 77 patients with advanced solid tumors carrying the TP53 Y220C mutation. The oral drug was generally well tolerated, with few dose‑limiting toxicities, allowing the selection of a...
By GEN (Genetic Engineering & Biotechnology News)
News•Feb 26, 2026
Increasing Rice Yields with Gene-Informed Selective Breeding
An international team led by Oxford, Nanjing Agricultural University and the Chinese Academy of Sciences identified the rice gene OsWRI1a as a key regulator of growth under varying nitrogen levels. Over‑expressing a strong OsWRI1a allele increased root‑to‑shoot ratios and grain...
By GEN (Genetic Engineering & Biotechnology News)
News•Feb 25, 2026
ADMET Predictions Get AI Boost, Federated Data Network Unites Pharma
Apheris has launched the ADMET Network, a federated learning platform that lets pharmaceutical companies jointly train ADMET prediction models without exposing raw data. Five founding members—Lundbeck, Orion Pharma, Recursion, Servier and an undisclosed partner—have each contributed roughly 80% of their...
By GEN (Genetic Engineering & Biotechnology News)
News•Feb 25, 2026
Bridging the Translation Gap for Regenerative Tissues
Muvon Therapeutics, a clinical‑stage company developing regenerative muscle treatments, is confronting the translation gap between academic discovery and commercial manufacturing. The firm highlights three core hurdles: co‑developing evolving regulatory frameworks, automating novel manufacturing processes, and recruiting personnel with GMP expertise....
By GEN (Genetic Engineering & Biotechnology News)
News•Feb 25, 2026
Autonomy and Accountability in Bioprocessing
Artificial intelligence is transitioning from offline analysis to active laboratory roles, yet bioprocess engineering faces unique biological and regulatory hurdles. A recent review advocates hybrid laboratories that blend AI‑driven automation for core tasks with human oversight for auxiliary processes. High‑throughput...
By GEN (Genetic Engineering & Biotechnology News)
News•Feb 25, 2026
Samsung Joins CEPI Vaccine Network to Prepare for Next Pandemic
Samsung Biologics has joined the Coalition for Epidemic Preparedness Innovations (CEPI) Vaccine Manufacturing Facility Network, committing to develop a ready‑to‑activate recombinant protein vaccine platform. Backed by a $20 million budget, Samsung will pre‑agree manufacturing processes, run simulated outbreak drills, and prepare...
By GEN (Genetic Engineering & Biotechnology News)
News•Feb 25, 2026
Fermenter-Extractor-Separator Mixes Uniformly and Is Gentle on Cells
Researchers at Iowa State University have unveiled a Taylor Vortex Fermenter‑Extractor‑Separator that combines fermentation, extraction and separation in a single unit. The concentric‑cylinder design creates Taylor vortices, delivering uniform mixing while minimizing cell damage. Higher mass‑transfer rates cut gas consumption,...
By GEN (Genetic Engineering & Biotechnology News)
News•Feb 25, 2026
Processing and Interpreting Untargeted Metabolomics Data for Biomarker Discovery and Drug Development
Panome Bio has launched MassID™, a cloud‑based platform that streamlines the processing and interpretation of untargeted LC/MS metabolomics data. The system delivers an end‑to‑end pipeline that cleans, normalizes, and annotates raw spectra while assigning probability‑based confidence scores and global false...
By GEN (Genetic Engineering & Biotechnology News)
News•Feb 24, 2026
New Protein-Like Polymers Target, Degrade “Undruggable” Proteins Driving Cancer
Researchers at Northwestern University have created HYDRACs, hybrid degrading copolymers that bind and eliminate traditionally "undruggable" oncogenic proteins such as MYC and KRAS. The polymers display target‑recognizing peptides on one side and degron motifs on the other, directing the proteins...
By GEN (Genetic Engineering & Biotechnology News)
News•Feb 24, 2026
Beam Designs New Approach for Direct Correction of Mutations Causing PKU
Beam Therapeutics announced BEAM-304, a liver‑targeted base‑editing program aimed at correcting PAH gene mutations that cause phenylketonuria (PKU). The approach uses multiple mutation‑specific editors within a single clinical development pathway, initially focusing on the two most common U.S. variants that...
By GEN (Genetic Engineering & Biotechnology News)
News•Feb 24, 2026
Drug-Controlled CAR T Cells May Enable Safer Immunotherapy
Researchers at EPFL have created a drug‑controlled CAR‑T platform called DROP‑CAR that can be turned off on demand with the FDA‑approved BCL‑2 inhibitor venetoclax. The system places a reversible protein‑protein interaction on the cell surface, causing the CAR to dissociate...
By GEN (Genetic Engineering & Biotechnology News)
Deals•Feb 24, 2026
Beam Therapeutics Secures $500M Strategic Financing From Sixth Street
Beam Therapeutics announced a $500 million strategic financing agreement with Sixth Street to fund the potential launch of its sickle cell disease therapy and advance its BEAM‑304 program for phenylketonuria. The financing will support development of the gene‑editing platform and...
GEN (Genetic Engineering & Biotechnology News)
News•Feb 23, 2026
What the FDA’s Priority Voucher Decision Means for Psychedelic Drug Development
The FDA’s Commissioner’s National Priority Review Voucher (CNPV) pilot compresses review timelines to one‑to‑two months for qualifying drugs, but its criteria favor applications with mature data packages. Compass Pathways’ synthetic psilocybin (COMP360) was listed as eligible yet did not receive...
By GEN (Genetic Engineering & Biotechnology News)
News•Feb 23, 2026
Before AGBT Kicks Off, Ultima Unveils the UG 200
Ultima Genomics announced the UG 200 series, a second‑generation sequencing platform that includes a single‑wafer UG 200 and a dual‑wafer UG 200 Ultra. Both instruments are half the size of the UG 100, cost less (starting at $850,000), and deliver...
By GEN (Genetic Engineering & Biotechnology News)
News•Feb 20, 2026
How to Avoid a Fall by Balancing Cost and Performance in Drug Discovery
Balancing cost and performance in drug discovery requires a hybrid engineering‑led approach that combines on‑premise HPC with scalable cloud resources. Uncontrolled cloud scaling can drive unpredictable expenses, while pure on‑premise systems demand high upfront capital and maintenance. By implementing disciplined...
By GEN (Genetic Engineering & Biotechnology News)